Alexander Stark and Guido Eibl from the University of California, Los Angeles authored a clinical overview of pancreatic ductal adenocarcinoma (PDAC). The text discusses epidemiology, tumor biology, diagnosis, treatment, and prognosis, noting that 80-90% of patients have surgically incurable disease at presentation. It excludes pancreatic neuroendocrine tumors and cancer arising from cystic lesions.
Use Cases
- Summarize PDAC epidemiology and tumor biology based on the overview text
- Inform patient education materials based on the sections covering diagnosis, treatment, and prognosis
- Compare clinical management approaches for PDAC based on the treatment discussion
- Identify gaps in PDAC research based on the stated poor prognosis despite advances
Strengths
- Authored by researchers from a specialized institution (University of California, Los Angeles)
- Focuses on a specific cancer subtype (PDAC) with clear exclusion criteria for other variants
- Includes specific clinical statistics, such as the 80-90% rate of surgically incurable disease at presentation
Limitations
- Row count is unknown, which may limit suitability assessment
- Column-level documentation is absent; field semantics must be inferred after download
- Last update date is unknown; freshness unverified
Provenance
- Source
- University of California, Los Angeles